Sign in

CIK 0001885522 · Non-accelerated filer<br>Smaller reporting company

Neumora Therapeutics, Inc.

Sign in to watch
Ticker
NMRA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
844367680
Phone
(857) 760-0900
Business address
260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$701,641
in 2 filings

Net −$701,641. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Aurora Daljit Singh −$702K See Remarks sold 100% of stake
Date Insider Transaction Shares Price Value Owned after
2023-09-19 ARCH Venture Partners X, LLC 10% owner Conversion · Series B Preferred Stock −2,124,143 0
2023-09-19 ARCH Venture Partners X, LLC 10% owner Conversion +684,167 684,167
2023-09-19 ARCH Venture Partners X, LLC 10% owner Conversion +1,144,973 1,144,973
2023-09-19 ARCH Venture Partners X, LLC 10% owner Conversion +6,895,021 12,205,379
2023-09-19 ARCH Venture Partners X, LLC 10% owner Conversion +6,576,400 11,886,758
2023-09-19 ARCH Venture Partners X, LLC 10% owner Conversion +2,124,143 2,124,143
2023-09-19 ARCH Venture Partners X, LLC 10% owner Purchase +1,500,000 $17.00 $25.5M 3,624,143
2023-09-19 ARCH Venture Partners X, LLC 10% owner Conversion · Series A-1 Preferred Stock −684,167 0
2023-09-19 ARCH Venture Partners X, LLC 10% owner Conversion · Series A-1 Preferred Stock −1,144,973 0
2023-09-19 ARCH Venture Partners X, LLC 10% owner Conversion · Series A-2 Preferred Stock −6,895,021 0
2023-09-19 ARCH Venture Partners X, LLC 10% owner Conversion · Series A-2 Preferred Stock −6,576,400 0
2023-09-19 ARCH Venture Partners X, LLC 10% owner Conversion · Series B Preferred Stock −2,124,143 0
2023-09-19 Gosebruch Henry O President & CEO Purchase +15,000 $12.62 $189K 15,000
2023-09-19 AMGEN INC 10% owner Conversion +33,603,948 33,603,948
2023-09-19 AMGEN INC 10% owner Purchase +1,764,705 $17.00 $30.0M 35,368,653
2023-09-19 AMGEN INC 10% owner Conversion · Series A-2 Preferred Stock −32,754,291 0
2023-09-19 AMGEN INC 10% owner Conversion · Series B Preferred Stock −849,657 0
2023-09-14 Lenz Robert A. Head of R&D Grant or award +352,941 352,941
2023-09-14 Lenz Robert A. Head of R&D Grant or award · Stock Option (Right to Buy) +502,934 502,934
2023-09-14 Piacquad David Director Grant or award · Stock Option (Right to Buy) +46,455 46,455

Page 19 of 20 · 384 trades